Singapore, December 19, 2013 – Vela Diagnostics today announced the launch of the Sentosa SA NRAS PCR Test for detecting mutations relevant to melanoma and thyroid cancers.

The Sentosa SA NRAS PCR Test is the latest addition to Vela Diagnostics qPCR oncology panel, which includes tests for the detection of BRAF and the upcoming KRAS test. The Sentosa SA NRAS PCR Test is the only automated NRAS qPCR test available in the market. Currently available for Research Use Only, this assay is currently pending CE-IVD approval. Vela Diagnostics’ oncology product offering will be further expanded by the addition of Next-Generation Sequencing tests in 2014. NRAS is a member of the RAS family of oncogenes and is associated with the efficacy of drugs targeted for malignant melanoma.

The Sentosa SA NRAS PCR Test is validated as part of the automated Sentosa qPCR workflow. The workflow requires minimum hands-on time and sample input. It is supported by automated reporting and middleware capability to allow for sample traceability, reliable result calling and seamless laboratory integration. To date, the Sentosa qPCR workflow supports more than 20 tests for clinical and research use depending on regional availability, and is designed to improve laboratory efficiency and cost effectiveness. 

“We are excited to be the first in the market to launch an NRAS test that is highly sensitive and robust to detect NRAS mutations. With recent on-going clinical trials, this will be a revolutionary test for companion diagnostics,” said Vela Diagnostics CEO Michael Tillman.

Updated: April 25, 2014